-
EP4003400
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4003400
| EP4003400 - DOSING FOR PREVENTION OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) WITH IL-22 FC FUSION PROTEINS [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 01.03.2024 Database last updated on 03.09.2024 | |
| Former | Grant of patent is intended Status updated on 30.10.2023 | ||
| Former | Examination is in progress Status updated on 23.06.2023 | ||
| Former | Request for examination was made Status updated on 29.04.2022 | ||
| Former | The international publication has been made Status updated on 05.02.2021 | ||
| Former | unknown Status updated on 24.08.2020 | Most recent event Tooltip | 01.03.2024 | (Expected) grant | published on 03.04.2024 [2024/14] | Applicant(s) | For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [2022/22] | Inventor(s) | 01 /
KALO, Matthew 1 DNA Way South San Francisco, CA 94080-4990 / US | 02 /
LU, Timothy Then-Chioh 1 DNA Way South San Francisco, CA 94080-4990 / US | 03 /
PECK, Melicent Clare 1 DNA Way South San Francisco, CA 94080-4990 / US | 04 /
SUKUMARAN, Siddharth 1 DNA Way South San Francisco, CA 94080-4990 / US | 05 /
WANG, Yehong 1 DNA Way South San Francisco, CA 94080-4990 / US | 06 /
WONG, Chin Yat 1 DNA Way South San Francisco, CA 94080-4990 / US | 07 /
DAY, Peter William 1 DNA Way South San Francisco, CA 94080-4990 / US | [2023/48] |
| Former [2022/22] | 01 /
KALO, Matthew 1 DNA Way South San Francisco, CA 94080-4990 / US | ||
| 02 /
LU, Timothy Then-Chioh 1 DNA Way South San Francisco, CA 94080-4990 / US | |||
| 03 /
PECK, Melicent Clare 1 DNA Way South San Francisco, CA 94080-4990 / US | |||
| 04 /
SUKUMARAN, Siddharth 1 DNA Way South San Francisco, CA 94080-4990 / US | |||
| 05 /
WANG, Yehong 1 DNA Way South San Francisco, CA 94080-4990 / US | |||
| 06 /
WONG, Chin Yat 1 DNA Way South San Francisco, CA 94080-4990 / US | |||
| 07 /
DAY, Peter William 1 DNA Way South San Francisco, CA 94080-4990 / US | Representative(s) | Klostermeyer-Rauber, Dörte F. Hoffmann-La Roche AG Corporate Law Patents (CLP) Grenzacherstrasse 124 4070 Basel / CH | [2022/22] | Application number, filing date | 20757034.2 | 24.07.2020 | [2022/22] | WO2020US43542 | Priority number, date | US201962879306P | 26.07.2019 Original published format: US 201962879306 P | US202062976321P | 13.02.2020 Original published format: US 202062976321 P | [2022/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021021647 | Date: | 04.02.2021 | Language: | EN | [2021/05] | Type: | A1 Application with search report | No.: | EP4003400 | Date: | 01.06.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.02.2021 takes the place of the publication of the European patent application. | [2022/22] | Type: | B1 Patent specification | No.: | EP4003400 | Date: | 03.04.2024 | Language: | EN | [2024/14] | Search report(s) | International search report - published on: | EP | 04.02.2021 | Classification | IPC: | A61K38/20, A61P37/06, C07K14/54, C07K19/00 | [2022/22] | CPC: |
A61K38/20 (EP,CN,IL,KR,US);
A61K31/436 (CN,IL,KR,US);
A61K31/519 (CN,IL,KR,US);
A61K35/28 (CN,IL,US);
A61K38/13 (CN,IL,KR,US);
A61K45/06 (CN,IL,KR,US);
A61K9/0019 (IL,US);
A61P37/06 (EP,CN,IL,KR,US);
C07K14/54 (EP,CN,IL,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/22]
| Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | DOSIERUNG ZUR VORBEUGUNG ODER BEHANDLUNG VON GRAFT-VERSUS-HOST-KRANKHEIT (GVHD) MIT IL-22-FC-FUSIONSPROTEINEN | [2022/22] | English: | DOSING FOR PREVENTION OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) WITH IL-22 FC FUSION PROTEINS | [2022/22] | French: | DOSAGE POUR LA PRÉVENTION OU LE TRAITEMENT DE LA MALADIE DU GREFFON CONTRE L'HÔTE (GVHD) AVEC DES PROTÉINES DE FUSION IL-22-FC | [2022/22] | Entry into regional phase | 28.02.2022 | National basic fee paid | 28.02.2022 | Designation fee(s) paid | 28.02.2022 | Examination fee paid | Examination procedure | 28.02.2022 | Examination requested [2022/22] | 28.02.2022 | Date on which the examining division has become responsible | 19.09.2022 | Amendment by applicant (claims and/or description) | 22.06.2023 | Despatch of a communication from the examining division (Time limit: M02) | 03.09.2023 | Reply to a communication from the examining division | 31.10.2023 | Communication of intention to grant the patent | 23.02.2024 | Fee for grant paid | 23.02.2024 | Fee for publishing/printing paid | 23.02.2024 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 28.06.2022 | Renewal fee patent year 03 | 20.07.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]WO2014145016 (GENENTECH INC [US], et al) [I] 1-67 * page 12, line 5 - line 21 * * page 31, line 10 - line 27 *; | [I]WO2015070077 (SLOAN KETTERING INST CANCER [US], et al) [I] 1-67 * paragraphs [0007] , [0009] *; | [I]US2018355009 (SCHEER JUSTIN [US], et al) [I] 1-67 * paragraph [0024] *; | [XP]WO2019148026 (GENENTECH INC [US], et al) [XP] 1-67 * page 1, line 34 - page 2, line 4 * * page 117, line 28 - page 119, line 6 *; | [XP]WO2019148020 (GENENTECH INC [US], et al) [XP] 1-67 * page 7, line 21 - line 26 * * page 47, line 15 - page 48, line 16 *; | [XP]WO2019165140 (GENENTECH INC [US], et al) [XP] 1-67 * page 47, line 15 - page 48, line 16 *; | [I] - LINDEMANS CAROLINE A ET AL, "IL-22 Is an Intestinal Stem Cell Growth Factor, and IL-22 Administration in Vivo Reduces Morbidity and Mortality in Murine GvHD", BLOOD, & 56TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2014, (201412), vol. 124, no. 21, XP009523729 [I] 1-67 * abstract * DOI: http://dx.doi.org/10.1182/blood.V124.21.651.651 | [I] - LINDEMANS CAROLINE A ET AL, "IL-22 Directly Regulates Intestinal Stem Cells, Protecting Epithelium from GvHD and Reducing GvHD Mortality", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, (2015), vol. 21, no. 2, doi:10.1016/J.BBMT.2014.11.058, ISSN 1083-8791, XP029133484 [I] 1-67 * abstract * DOI: http://dx.doi.org/10.1016/j.bbmt.2014.11.058 | [A] - CAROLINE A. LINDEMANS ET AL, "Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration", NATURE, London, (20151209), vol. 528, no. 7583, doi:10.1038/nature16460, ISSN 0028-0836, pages 560 - 564, XP055383955 [A] 1-67 * abstract * DOI: http://dx.doi.org/10.1038/nature16460 | [A] - OLIVIA B. PARKS ET AL, "Interleukin-22 Signaling in the Regulation of Intestinal Health and Disease", FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, (20160113), vol. 3, no. 85, doi:10.3389/fcell.2015.00085, pages 1 - 13, XP055580794 [A] 1-67 * abstract * DOI: http://dx.doi.org/10.3389/fcell.2015.00085 | [A] - YUSUKE SHONO ET AL, "Gut microbiota injury in allogeneic haematopoietic stem cell transplantation", NATURE REVIEWS CANCER, London, (20180216), vol. 18, no. 5, doi:10.1038/nrc.2018.10, ISSN 1474-175X, pages 283 - 295, XP055719222 [A] 1-67 * abstract * DOI: http://dx.doi.org/10.1038/nrc.2018.10 | [A] - MICHAEL E. ROTHENBERG ET AL, "-22Fc): A Potential Therapy for Epithelial Injury", CLINICAL PHARMACOLOGY AND THERAPEUTICS, US, (20190109), vol. 105, no. 1, doi:10.1002/cpt.1164, ISSN 0009-9236, pages 177 - 189, XP055744981 [A] 1-67 * abstract * DOI: http://dx.doi.org/10.1002/cpt.1164 | by applicant | US5821333 | US7642228 | US2011287009 | US2012059810 | - OUYANG et al., Annu. Rev. Immunol., vol. 29, pages 159 - 63 | - CLARKSON et al., Nature, (19910000), vol. 352, pages 624 - 628 | - KINDT et al., Essentials of Glycobiology, Cold Spring Harbor Laboratory Press, (20070000), pages 2015 - 2017 | - PORTOLANO et al., J. Immunol., (19930000), vol. 150, pages 880 - 887 | - HARRIS et al., Biol. Blood Marrow Transplant., (20160000), vol. 22, pages 4 - 10 | - GLUCKSBERG H et al., Transplantation, (19740000), vol. 18, no. 4, pages 295 - 304 | - FILIPOVICH et al., Biol. Blood. Marrow Transplant., (20050000), vol. 11, pages 945 - 955 | - JAGASIA et al., Biol. Blood. Marrow Transplant., (20150000), vol. 21, no. 3, pages 389 - 401 | - JAGASIA et al., Biol. Blood Marrow Transplant., (20150000), vol. 21, pages 389 - 401 | - HARRIS et al., Biol Blood Marrow Transplant, (20160000), vol. 22, pages 4 - 10 | - COOKE et al., Biol. Blood Marrow Transplant, (20170000), vol. 23, pages 211 - 234 | - GATZA et al., Int. J. Hematol. Oncol., (20150000), vol. 4, no. 3, pages 113 - 126 |